You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Comparison of outcomes for patients not treated with MTX (Group 1), treated with MTX by intramuscular injection (Group 2) or treated with MTX by intravenous injection (Group 3)

From: Management of Caesarean scar pregnancy with or without methotrexate before curettage: human chorionic gonadotropin trends and patient outcomes

  Mean ± SD/Rate P value
Group 1(n = 47) Group 2(n = 46) Group 3(n = 14)  
Intraoperative blood loss (ml) 39.83 ± 16.96 55.33 ± 44.19 42.86 ± 22.68 0.066
Pregnancy tissue retained, n (%) 1(2.1%) 2(4.3%) 1(7.1%) 0.658
Hospital stay (days) 7.00 ± 2.29 9.59 ± 2.46 13.86 ± 3.88 <0.001